(±)-2-methoxy-3-phenylpropan-1-amine | 883545-49-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (±)-2-methoxy-3-phenylpropan-1-amine
• 英文别名: 2-Methoxy-3-phenyl-1-propanamine；2-methoxy-3-phenylpropan-1-amine
• CAS: 883545-49-1
• 化学式: C₁₀H₁₅NO
• 分子量: 165.235
• InChiKey: DIOGSRGTNMACOE-UHFFFAOYSA-N

物化性质

• 沸点：
  254.8±28.0 °C(Predicted)
• 密度：
  0.997±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  (4Z)-4-(1,3-benzothiazol-6-ylmethylene)-2-methylsulfanyl-1H-imidazol-5-one 、 (±)-2-methoxy-3-phenylpropan-1-amine 以 四氢呋喃 为溶剂， 以61 %的产率得到(±)-(Z)-5-(benzo[d]thiazol-6-ylmethylene)-2-((2-methoxy-3-phenylpropyl)amino)-3,5-dihydro-4H-imidazol-4-one
  参考文献：
  名称：

  Leucettinibs，一类 DYRK/CLK 激酶抑制剂，灵感源自海洋海绵天然产物 Leucetamine B

  摘要：

  双特异性酪氨酸磷酸化调节激酶 (DYRK) 和 cdc2 样激酶 (CLK) 最近因其在各种病理学中的重要参与而引起了人们的关注。我们在此描述了一系列源自亮氨酰胺和海洋天然产物亮氨酰胺 B 的 DYRK/CLK 抑制剂。合成了 45 种带有融合的 [6 + 5]-杂芳基亚甲基的N 2-官能化 2-氨基咪唑啉-4-酮。苯并噻唑-6-基亚甲基被选为 15 个不同杂芳基亚甲基中最有效的残基。合成并广泛表征了186 个带有苯并噻唑-6-基亚甲基的N 2-取代 2-氨基咪唑啉-4-酮，统称为 Leucettinib。鉴定出亚纳摩尔 IC 50 （DYRK1A 为 0.5-20 nM）抑制剂，并在 DYRK1A 中对一种 Leucettinib 进行建模，并与 CLK1 和较弱抑制的脱靶 CSNK2A1 共结晶。合成了 Leucettinib 的激酶失活异构体（DYRK1A 上 >3–10 μM），称为

  DOI：

  10.1021/acs.jmedchem.3c00884
• 作为产物：
  描述：

  (3-Azido-2-methoxypropyl)benzene 在 palladium 10% on activated carbon 氢气 作用下， 以 乙醇 为溶剂， 反应 24.0h， 以49%的产率得到(±)-2-methoxy-3-phenylpropan-1-amine
  参考文献：
  名称：

  [EN] FLAVIN DERIVATIVES
  [FR] DÉRIVÉS DE FLAVINE

  摘要：

  本发明涉及新型黄素衍生物，其用途和用作核糖开关配体和/或抗感染剂的组合物。

  公开号：

  WO2011126567A1

文献信息

• [EN] ADRENERGIC RECEPTOR MODULATING COMPOUNDS AND METHODS OF USING THE SAME<br/>[FR] COMPOSÉS DE MODULATION DES RÉCEPTEURS ADRÉNERGIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：UNIV LELAND STANFORD JUNIOR

  公开号：WO2017197324A1

  公开（公告）日：2017-11-16

  Adrenergic receptor modulating compounds and methods of using the same are provided. Also provided are methods of treating a subject for a disease or condition associated with an adrenergic receptor including administering a therapeutically effective amount of the subject compound. Aspects of the disclosure include a method of modulating an inflammatory pathway in a cell, such as the production of TNF-alpha in the cell. The method can include contacting a cell with a β1-selective adrenergic receptor modulating compound to selectively activate a cAMP pathway over a beta-arrestin pathway in the cell. Pharmaceutical compositions and kits which include the subject compounds are provided.

  提供了调节肾上腺素受体的化合物及使用方法。还提供了治疗与肾上腺素受体相关疾病或症状的方法，包括向受试者施用治疗有效量的该化合物。本公开的方面包括一种调节细胞中炎症通路的方法，例如在细胞中产生TNF-alpha。该方法可以包括将细胞与β1选择性肾上腺素受体调节化合物接触，以在细胞中选择性激活cAMP通路而不是β-arrestin通路。还提供了包含该化合物的药物组合物和试剂盒。
• FLAVIN DERIVATIVES
  申请人：Coish Philip D. G.

  公开号：US20130029980A1

  公开（公告）日：2013-01-31

  The present invention relates novel flavin derivatives, their use and compositions for use as riboswitch ligands and/or anti-infectives.

  本发明涉及新型黄素衍生物，其用途和组合物，用作核糖开关配体和/或抗感染剂。
• Adrenergic receptor modulating compounds and methods of using the same
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：US11173144B2

  公开（公告）日：2021-11-16

  Adrenergic receptor modulating compounds and methods of using the same are provided. Also provided are methods of treating a subject for a disease or condition associated with an adrenergic receptor including administering a therapeutically effective amount of the subject compound. Aspects of the disclosure include a method of modulating an inflammatory pathway in a cell, such as the production of TNF-alpha in the cell. The method can include contacting a cell with β1-selective adrenergic receptor modulating compound to selectively activate a cAMP pathway over a beta-arrestin pathway in the cell. Pharmaceutical compositions and kits which include the subject compounds are provided.

  提供了肾上腺素能受体调节化合物及其使用方法。还提供了治疗与肾上腺素能受体相关的疾病或病症的方法，包括施用治疗有效量的主体化合物。本公开的各个方面包括一种调节细胞中炎症通路的方法，如细胞中 TNF-α 的产生。该方法可包括使细胞与β1选择性肾上腺素能受体调节化合物接触，以选择性地激活细胞中的cAMP通路而不是β-arrestin通路。本发明还提供了包括上述化合物的药物组合物和试剂盒。
• Trichloroacetamidines, a new class of positive inotropic agents
  作者：Walfred S. Saari、Mark B. Freedman、Joel R. Huff、Stella W. King、Andrew W. Raab、Susan J. Bergstrand、Edward L. Engelhardt、Alexander Scriabine、George Morgan

  DOI：10.1021/jm00210a021

  日期：1978.12

  A series of trichloroacetamidine derivatives, obtained by addition of amines to trichloroacetonitrile, was evaluated for positive inotropic activity on isolated cat heart papillary muscles. Increased contractility, not antagonized by beta-adrenergic blockade with sotalol or reserpine pretreatment, was observed in this assay with a variety of N-substituted trichloroacetamidine derivatives. More extensive pharmacological studies with the 3-indolylmethyl analogue 2 showed that this amidine in dogs, 5 mg/kg iv, produced a positive inotropic effect more pronounced than that of ouabain, 50 microgram/kg iv. Several of the trichloroacetamidines were found to be inhibitors of guinea pig kidney and calf heart Na-K-dependent ATPase and to have specificity for these enzymes different from that of ouabain. Bacterial mutagenic activity was observed with three members, 2,3, and 12, of the series.
• BENZIMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION
  申请人：BRITISH BIO-TECHNOLOGY LIMITED

  公开号：EP0543861A1

  公开（公告）日：1993-06-02